ArticleJournal of gastrointestinal cancer2026
Post-neoadjuvant Metabolic Response Assessed by ¹⁸F-FDG PET/CT Predicts Pathologic Complete Response and Survival in Esophageal Squamous Cell Carcinoma Treated with the CROSS Regimen.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic response on ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) after neoadjuvant chemoradiotherapy may predict pathologic complete response (pCR) in esophageal squamous cell carcinoma (ESCC). However, optimal imaging timing and thresholds for percentage change in standardized uptake value (SUVmax) remain undefined in homogeneous cohorts.
methodsThis retrospective study included 110 consecutive patients with mid- or lower-third ESCC treated with the CROSS regimen (41.4 Gy radiotherapy plus weekly paclitaxel/carboplatin) between 2017 and 2024. All underwent baseline (PET0) and post-treatment (PET1; 6-10 weeks) FDG PET/CT. Percentage reduction in maximum SUVmax was calculated for the primary tumor and involved lymph nodes. Primary endpoint was pCR (ypT0N0); secondary endpoint was overall survival (OS).
resultspCR was achieved in 62 patients (56.3%). Mean percentage reduction in tumor SUVmax was 83.3% in pCR patients versus 70.5% in non-pCR patients (P < 0.001); nodal reduction was 60.4% versus 40.2% (P < 0.001). Receiver operating characteristic analysis identified ≥ 67% reduction in tumor SUVmax as optimal (AUC 0.634, 95% CI 0.530-0.739; sensitivity 80%, specificity 56%). Multivariate logistic regression confirmed tumor SUVmax reduction (OR 1.025 per 1% increase; P = 0.011) and nodal SUVmax reduction (OR 1.009; P = 0.034) as independent pCR predictors. Median OS was 38 months with pCR versus 33 months without (log-rank P = 0.023). Cox regression showed HR 0.51 for pCR (95% CI 0.28-0.94; P = 0.030) and 0.58 for ≥ 67% tumor SUVmax reduction (P = 0.086).
conclusionIn patients with esophageal squamous cell carcinoma treated with the CROSS regimen, a ≥ 67% reduction in primary tumor SUVmax on FDG PET/CT at 6-10 weeks after neoadjuvant chemoradiotherapy is an independent predictor of pathologic complete response with high sensitivity. However, the moderate specificity and area under the curve suggest that this metabolic parameter should be interpreted cautiously and integrated with multimodal assessment rather than used in isolation.
Indexed as
Identifiers
42171848What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.